Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 31;10(11):2437.
doi: 10.3390/jcm10112437.

Cataract Surgery with Intraocular Lens Implantation in Juvenile Idiopathic Arthritis-Associated Uveitis: Outcomes in the Era of Biological Therapy

Affiliations

Cataract Surgery with Intraocular Lens Implantation in Juvenile Idiopathic Arthritis-Associated Uveitis: Outcomes in the Era of Biological Therapy

Elena Bolletta et al. J Clin Med. .

Abstract

This study compared the outcomes of cataract surgery with intraocular lens (IOL) implantation in patients with juvenile idiopathic arthritis (JIA)-associated chronic anterior uveitis treated with antimetabolite drugs and systemic corticosteroids (Non-Biological Group) versus patients treated with antimetabolites and biological drugs (Biological Group). A cohort of patients with cataract in JIA-associated uveitis undergoing phacoemulsification with IOL implantation was retrospectively evaluated. The main outcome was a change in corrected distance visual acuity (CDVA) in the two groups. Ocular and systemic complications were also recorded. The data were collected preoperatively and at 1, 12, and 48 months after surgery. Thirty-two eyes of 24 children were included: 10 eyes in the Non-Biological Group and 22 eyes in the Biological Group. The mean CDVA improved from 1.19 ± 0.72 logMAR preoperatively to 0.98 ± 0.97 logMAR at 48 months (p = 0.45) in the Non-Biological Group and from 1.55 ± 0.91 logMAR preoperatively to 0.57 ± 0.83 logMAR at 48 months (p = 0.001) in the Biological Group. The postoperative complications, including synechiae, cyclitic membrane, IOL explantation, glaucoma, and macular edema, were not statistically different between the two groups. An immunosuppressive treatment with biological drugs can improve the visual outcome after cataract surgery in patients with JIA-associated uveitis, but it does not significantly reduce postoperative ocular complications.

Keywords: IOL; JIA; biologicals; cataract surgery; intraocular lens; juvenile idiopathic arthritis; uveitis.

PubMed Disclaimer

Conflict of interest statement

No conflicting relationship exists for any author.

Figures

Figure 1
Figure 1
Mean CDVA and 95% CI in the 2 groups before and 12 months after surgery.
Figure 2
Figure 2
GLM repeated measure for CDVA in the 2 groups (estimated marginal means with 95% CI). GLM = generalized linear model; CDVA = corrected distance visual acuity.
Figure 3
Figure 3
Mean CDVA changes in the 2 groups during follow-up. CDVA = corrected distance visual acuity.

Similar articles

Cited by

References

    1. Magli A., Forte R., Rombetto L., Alessio M. Cataract management in juvenile idiopathic arthritis: Simultaneous versus secondary intraocular lens implantation. Ocul. Immunol. Inflamm. 2014;22:133–137. doi: 10.3109/09273948.2013.834062. - DOI - PubMed
    1. Kump L.I., Castañeda R.A.C., Androudi S.N., Reed G.F., Foster C.S. Visual Outcomes in Children with Juvenile Idiopathic Arthritis-Associated Uveitis. Ophthalmology. 2006;113:1874–1877. doi: 10.1016/j.ophtha.2006.05.016. - DOI - PubMed
    1. BenEzra D., Cohen E., Behar-Cohen F. Uveitis and juvenile idiopathic arthritis: A cohort study. Clin. Ophthalmol. 2007;1:513–518. - PMC - PubMed
    1. Phatak S., Lowder C., Pavesio C. Controversies in intraocular lens implantation in pediatric uveitis. J. Ophthalmic Inflamm. Infect. 2016;6 doi: 10.1186/s12348-016-0079-y. - DOI - PMC - PubMed
    1. Angeles-Han S., Yeh S. Prevention and management of cataracts in children with juvenile idiopathic arthritis-associated uveitis. Curr. Rheumatol. Rep. 2012;14:142–149. doi: 10.1007/s11926-011-0229-z. - DOI - PMC - PubMed